Company news: CVS, LiveStrong

Share this article:
CVS is getting serious about generics, and has knocked off a few brand names from its PBM formulary for 2013, reported the Wall Street Journal. The Journal noted that the drugstore chain started eliminating high-cost prescriptions over the summer. Some of these have made their way back onto the formulary, including Lilly/BI's Tradjenta, but the drug store chain is striking Allergan's glaucoma medicine Lumigan, Pfizer's human growth hormone Genotropin and the BMS/AstraZeneca diabetes med Onglyza, reported the WSJ.

Shifting gears faster than some expected, the Livestrong Foundation and Lance Armstrong have parted ways, reported the New York Times. The disgraced cyclist and cancer survivor founded the Livestrong foundation in 1997. Although he resigned as chair, following the United States Anti-Doping Agency's conclusion that Armstrong was guilty of doping while competing for the Tour de France, he was still a member of the board until November 4, reported the Times. He was stripped of his Tour titles and banned from future Olympics sports. Jeff Garvey has replaced him as chairman.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.